2024-SABCS-Takeaways - 1

At 2024 SABCS®, experts advocated for
right-sizing treatments, increased focus
on risk reduction, early detection
R
ight-sizing breast
cancer treatment
was the key takehome
message from the
2024 San Antonio Breast
Cancer Symposium®,
and it was discussed in
virtually every session.
Symposium organizers,
clinical and patient
advocate presenters,
and most especially
the U.S. Food and
Drug Administration
(FDA) all focused on
optimizing and rightsizing
approaches
across medical oncology,
surgical oncology,
radiation oncology,
risk reduction, and
other areas.
A growing proportion
of patients are declaring
an explicit choice: quality
of life is at least as
important as quantity
of life. Right-sizing
treatment empowers
that choice by improving
cancer outcomes without
unacceptable changes to
quality of life.
There is growing
recognition by clinicians,
researchers, regulators,
and industry that
treatments patients
don't take don't
work. Improving the
tolerability of breast
cancer treatment is
a proven approach to
improving treatment
acceptance and uptake
in both clinical trials
and in the real world.
Assuming the treatment
is effective, improving
uptake has an enormous
potential to improve
oncologic outcomes.
Combination therapy
brings its own potential
2024 SABCS® BY THE NUMBERS
The 47th annual San Antonio Breast Cancer
Symposium® broke multiple records:
11,000+
Registered
Attendees
2,100+
Abstracts
Accepted
100+
Countries
Represented
December 10-13, 2024 | San Antonio, Texas
to improve
oncologic
outcomes.
Just as
combination
chemotherapy
offers
benefits,
so do
combinations
of targeted
agents, immune
checkpoint inhibitors,
endocrine therapy,
surgery, and radiation
therapy (RT). At least
one PARP inhibitor
appears to be a potent
radiosensitizer and can
improve RT outcomes.
It is unclear at this point
whether this is a singleagent
effect or class
effect, or even if it is
clinically useful because
of poor cosmesis, but
the potential is ripe for
investigation.
On a more practical
scale, combinations
such as neoadjuvant
pembrolizumab and
surgery have become
standard of care. But
too many patients
undergo surgery without
neoadjuvant therapy,
rendering surgery more
problematic and leaving
patients more vulnerable
to recurrence.
New this year at
SABCS® was a risk
reduction and early
detection track with four
sessions that explored
the latest on obesity
and breast cancer,
novel approaches to
breast cancer screening,
genetics in risk reduction
and early detection, and
new directions in breast
cancer prevention.
Keep reading for key
takeaways from the
meeting and remember
that the program is
available on demand for
registered attendees until
March 31, 2025. 
1
https://events.hubilo.com/sabcs2024/login https://events.hubilo.com/sabcs2024/login
2024-SABCS-Takeaways

Table of Contents for the Digital Edition of 2024-SABCS-Takeaways
